Data Sheet

Product Information

Catalog Number	BP22552
Product Name	Eribulin mesylate
Description	Eribulin mesylate (E7389 mesylate) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
In vitro	Eribulin (1-100 nM; 72 h) inhibits cells proliferation, with IC50s of 22.8 and 21.5 nM for LM8 and Dunn cells, respectively.Eribulin (10-50 nM; 12-72 h) increases early apoptosis significantly after 24 h treatment at the dose of 50 nM in LM8 cells.Eribulin (10-50 nM; 12-72 h) induces G2/M arrest by 12 h treatment with at the dose of 50 nM, but not by long-term treatment (72 h) with 10 nM in LM8 cells.Eribulin (1-50 nM; 12 h) does not induce senescence in LM8 cells.Eribulin (1-10 nM; 16 h) induces morphological change and suppresses cell migration in a low concentration in LM8 cells.
In vivo	Eribulin (1 mg/kg; i.v. once a week for 2 weeks) reduces primary tumor growth and lung metastasis of osteosarcoma in mice.Eribulin (1 mg/kg; once i.v.) suppresses circulating tumor cells (CTC) appearance in the low-concentration phase.
CAS No.	441045-17-6
Chemical Formula	C41H63NO14S
Molecular Weight	826
Solubility	DMSO: ≥ 100 mg/mL (121.07 mM) Ethanol: ≥ 100 mg/mL (121.07 mM)

Storage	Powder: -20°C for 2 years In solvent: -80°C for 1 year
Chemical Structure OR Tested Image	

Purdue Bioscience Inc.

750 50th St, Brooklyn, NY 11220, USA

https://www.purduebio.com

1-877.618.7311

info@purduebio.com

v2 Revision on 12/28/2022